Rakovina Therapeutics Inc. and NanoPalm Ltd. have announced a collaboration through a non-binding Letter of Intent (LOI) to establish a joint venture aimed at developing novel small-molecule oncology therapeutics. This partnership will commence with loading Rakovina’s dual-function PARP-HDAC inhibitor, kt3283, into Nano Palm’s patterned lipid nanoparticle (pLNP) technology. The integration of Rakovina’s AI-powered drug discovery platform and NanoPalm’s advanced pLNP delivery system is set to revolutionize precision and efficacy in therapeutic delivery within the oncology field.
kt3283, the primary development candidate in this proposed joint venture, is a potent small-molecule inhibitor targeting PARP and HDAC pathways crucial for cancer cell survival. Preclinical studies have exhibited the compound’s ability to induce DNA damage, disrupt cell-cycle progression, and enhance cytotoxicity compared to existing PARP and HDAC inhibitors. Strong efficacy has been observed in Ewing sarcoma, breast, and ovarian cancer models, with data presented at leading oncology conferences and published in a peer-reviewed journal.
NanoPalm’s pLNP technology, initially developed for gene therapy, employs AI-assisted formulation design to enhance tissue specificity, intracellular delivery, and systemic tolerability. This collaboration signifies the first application of NanoPalm’s pLNP platform to small-molecule therapeutics in oncology, offering the potential to significantly improve kt3283’s therapeutic index and tumor-specific delivery. Validated in multiple preclinical gene therapy programs, NanoPalm’s pLNP technology has demonstrated superior precision in delivery and biodistribution compared to traditional lipid nanoparticles.
The joint venture will focus on advancing kt3283 through late preclinical development and early clinical studies while exploring additional AI-derived drug candidates for inclusion in the development pipeline. Rakovina will provide the drug substance for kt3283 and other AI-discovered small-molecule candidates, along with in vitro and in vivo validation, pharmacology, toxicology, CMC data, and regulatory expertise. On the other hand, NanoPalm will contribute its pLNP platform, biomanufacturing capabilities, delivery science expertise, and preclinical and clinical support infrastructure based in Saudi Arabia.
The joint venture will be headquartered in Saudi Arabia, with a global development and commercialization mandate adhering to international regulatory standards. Intellectual property arising from the collaboration will be jointly owned, with each party retaining background IP and technology improvements. The partners plan to pursue third-party investments, non-dilutive grant opportunities, and share ownership, risks, and rewards equally.
Key Takeaways:
– Rakovina Therapeutics and NanoPalm Ltd. have signed an LOI to establish a joint venture focusing on developing novel oncology therapeutics.
– The collaboration integrates Rakovina’s AI-powered drug discovery platform with NanoPalm’s advanced pLNP delivery system for enhanced precision in therapeutic delivery.
– kt3283, a potent dual PARP-HDAC inhibitor, is the primary development candidate, showing promising results in preclinical studies across various cancer models.
– The joint venture will be based in Saudi Arabia, with a worldwide development and commercialization mandate under international regulatory standards.
Tags: formulation, biotech, clinical trials, regulatory, toxicology, nanomedicine, gene therapy, validation
Read more on finance.yahoo.com